Welcome to our dedicated page for Travere Therapeutics news (Ticker: TVTX), a resource for investors and traders seeking the latest updates and insights on Travere Therapeutics stock.
Travere Therapeutics Inc (TVTX) is a biopharmaceutical innovator developing therapies for rare kidney, liver, and metabolic diseases. This page provides a comprehensive repository of official company announcements, clinical trial updates, and regulatory developments.
Investors and researchers will find curated press releases detailing milestones for pipeline candidates like FILSPARI and sparsentan, along with financial disclosures and partnership announcements. Content is organized to highlight material events including FDA communications, trial phase completions, and strategic collaborations.
All updates are sourced directly from Travere Therapeutics to ensure accuracy. Bookmark this page for efficient tracking of the company’s progress in advancing treatments for IgA nephropathy, FSGS, and other rare conditions.
Travere Therapeutics (NASDAQ: TVTX) announced a presentation at the Society for the Study of Inborn Errors of Metabolism Annual Symposium in Freiburg, Germany, from August 30 to September 2, 2022. The focus will be on a genetic evaluation and cognitive function analysis from a longitudinal study related to classical homocystinuria (HCU). The study includes population-based estimates of HCU incidence and will showcase investigational enzyme replacement therapy, pegtibatinase, currently in Phase 1/2 trials. Authors will present findings during the poster walk on August 31, with details available electronically.
Travere Therapeutics (NASDAQ: TVTX) and CSL Vifor announced that the European Medicines Agency (EMA) has accepted the Conditional Marketing Authorization application for sparsentan, aimed at treating IgA nephropathy (IgAN). If approved in the second half of 2023, sparsentan would serve as the first non-immunosuppressive treatment for IgAN in Europe, addressing a significant unmet medical need. The EMA’s decision is supported by positive interim results from the pivotal Phase 3 PROTECT Study, showing a 49.8% reduction in proteinuria after 36 weeks. The treatment could potentially benefit over 100,000 IgAN patients in the U.S.
The European Medicines Agency (EMA) has accepted the Conditional Marketing Authorization (CMA) application for sparsentan, a treatment for IgA nephropathy (IgAN)
If approved, sparsentan will be a first-in-class non-immunosuppressive therapy addressing a significant unmet need in Europe. The application is supported by positive interim results from the PROTECT Study, showing a 49.8% reduction in proteinuria compared to 15.1% in controls, indicating strong efficacy.
On August 10, 2022, Travere Therapeutics (NASDAQ: TVTX) announced the granting of inducement equity grants to 29 new employees, comprising 101,500 restricted stock units (RSUs). These RSUs are part of the company’s efforts to attract talent and are issued outside of the 2018 Equity Incentive Plan, in compliance with Nasdaq rules. The RSUs will vest over four years, with 25% vesting annually, contingent on the employees’ continued service.
Travere focuses on developing treatments for rare diseases, emphasizing their commitment to patient care and innovative therapies.
Travere Therapeutics (TVTX) reported Q2 2022 financial results, posting total revenues of $54.2 million, comprising $51.0 million in net product sales and $3.2 million in licensing revenues. The company experienced a net loss of $67.0 million, compared to $39.0 million in Q2 2021. The FDA has accepted the NDA for accelerated approval of sparsentan for IgA nephropathy, with a PDUFA date set for November 17, 2022. Cash and equivalents stood at $553.2 million as of June 30, 2022, highlighting the company’s financial position as it aims for a potential launch of sparsentan.
Travere Therapeutics (NASDAQ: TVTX) has provided regulatory updates for its drug sparsentan aimed at treating IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS). The PDUFA target action date for sparsentan's NDA submission for IgAN remains on track for November 17, 2022. After FDA feedback, the company will pursue traditional approval for sparsentan in FSGS following the ongoing Phase 3 DUPLEX Study. Additionally, pegtibatinase received Breakthrough Therapy Designation for classical homocystinuria (HCU). A corporate conference call is scheduled for August 4, 2022.
Travere Therapeutics (NASDAQ: TVTX) is set to release its Q2 2022 financial results on August 4, 2022, before the U.S. market opens. A conference call will be held at 8:00 a.m. ET to discuss the results and offer a business update. For those unable to attend live, a replay will be available from 11:00 a.m. ET on August 4 until 11:00 a.m. ET on August 11, 2022. Travere Therapeutics focuses on developing therapies for rare diseases, aligning its operations with the urgent needs of patients and their families.
Travere Therapeutics (NASDAQ: TVTX) announced on July 10, 2022, that its Compensation Committee granted inducement restricted stock units (RSUs) to 43 new employees, totaling 120,700 shares. These RSUs, which vest over four years, were awarded outside of the 2018 Equity Incentive Plan as an inducement for new hires in compliance with Nasdaq Listing Rule 5635(c)(4). This initiative underscores Travere's commitment to attracting talent as it focuses on developing therapies for rare diseases.
Meissa Vaccines has appointed Frank Glavin as its new Chief Executive Officer, bringing over 20 years of biotech experience, including successful transitions from lab to clinic. Martin Moore, Ph.D., cofounder, will serve as Chief Scientific Officer. Under Glavin's leadership, Meissa aims to advance its AttenuBlock platform, focusing on intranasal vaccines for RSV and COVID-19. Current clinical data shows promising results for both vaccine candidates, with Phase 1 studies demonstrating safety and immunogenicity. The company is committed to tackling respiratory viral infections on a global scale.
On June 10, 2022, Travere Therapeutics (NASDAQ: TVTX) awarded inducement equity grants to ten new employees, comprising 48,750 restricted stock units (RSUs). These RSUs, granted outside the 2018 Equity Incentive Plan, will vest over four years with 25% vesting each year, contingent on continued employment. This initiative aligns with Nasdaq Listing Rule 5635(c)(4) and aims to attract new talent, enhancing the company's capabilities in developing therapies for rare diseases.
FAQ
What is the current stock price of Travere Therapeutics (TVTX)?
What is the market cap of Travere Therapeutics (TVTX)?
